Home-Based Transitional Cardiac Rehabilitation Trial With a Partially Randomized Patient Preference Design
A Confirmatory Non-Inferiority Trial of Home-Based Transitional Cardiac Rehabilitation, With a Partially Randomized Patient Preference (PRPP) Design, Informed by Pilot Data
This is a prospective, single-center, non-inferiority trial comparing a hospital-to-home transitional cardiac rehabilitation model with standard hospital-based cardiac rehabilitation in low-risk patients after cardiac surgery in Taiwan. Because patients' post-discharge scheduling constraints and treatment preferences make full randomization difficult to sustain in practice, the trial uses a Partially Randomized Patient Preference (PRPP) design: patients without a strong preference are randomized 1:1 to the two programs and form the randomized core cohort used for the primary confirmatory analysis, while patients with a clear, pre-specified preference are assigned accordingly and followed descriptively as a preference cohort. The primary hypothesis is that the hospital-to-home model is non-inferior to hospital-based rehabilitation in improving peak oxygen uptake (Peak VO2) after 8 weeks. A pre-specified key secondary hypothesis, based on an exploratory finding from the investigators' completed pilot study, is that the hospital-to-home model results in significantly lower 6-month outpatient medical costs. The trial does not include a no-treatment control arm; assay sensitivity is instead supported by the extensive existing evidence base for cardiac rehabilitation versus no treatment and for home-based versus center-based cardiac rehabilitation equivalence, following the constancy assumption described in ICH E10.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Rationale: A completed single-center pilot study (Cheng Hsin General Hospital institutional research grant, FY112) enrolled 30 patients (15 per arm, 4 withdrawals) and found a directional, exploratory signal of non-inferiority for the hospital-to-home model on Peak VO2, and a significant reduction in 6-month outpatient medical costs favoring the hospital-to-home arm. However, the pilot's original sample size was calculated using a two-tailed paired-sample t-test, which is not the correct method for a parallel-group non-inferiority design, so its non-inferiority conclusion was exploratory only. This confirmatory trial re-estimates the required sample size using the pilot's observed variance (ANCOVA-adjusted residual SD = 2.71 ml/min/kg) and the correct non-inferiority formula, and adopts a Partially Randomized Patient Preference (PRPP) design to address the real-world constraint that many post-discharge patients have strong scheduling or logistical preferences between an in-hospital and a home-based program.
Design: Prospective, parallel-group, non-inferiority trial with PRPP allocation. Patients without a strong preference (operationally defined as absence of a specific, identifiable scheduling, transportation, or technology-related constraint) are randomized 1:1 in permuted blocks to the hospital-to-home transitional model or hospital-based cardiac rehabilitation, forming the randomized core cohort (planned n=29 per arm, 58 total) that constitutes the intention-to-treat population for the primary confirmatory non-inferiority analysis. Patients with a clear, investigator-confirmed preference are assigned to their preferred program and followed as a preference cohort (planned n≈40) analyzed descriptively; their baseline characteristics are compared with the randomized core cohort to characterize potential selection effects, but they do not contribute to the primary confirmatory hypothesis test. Assuming approximately 60% of screened patients accept randomization (a planning assumption to be re-examined at the interim analysis), the overall enrollment target is 98 participants.
No-treatment control arm: The trial does not include a usual-care/no-rehabilitation control arm. The investigators considered a three-arm design to formally establish assay sensitivity but did not adopt it because (a) the effect of cardiac rehabilitation versus no treatment is already well established by a large existing evidence base, including the Cochrane meta-analyses cited in the 2026 ESC Guidelines on Cardiac Rehabilitation (85 RCTs / 23,430 patients in coronary artery disease; 60 RCTs / 8,728 patients in heart failure); (b) the equivalence of home-based and center-based cardiac rehabilitation has similarly been established at the meta-analytic level by the 2023 Cochrane review (24 RCTs, 3,046 patients); (c) adding a no-treatment arm would raise the enrollment target from 58 to approximately 134 in the randomized core cohort, which is not feasible for a single center; and (d) published hybrid cardiac rehabilitation non-inferiority/equivalence trials (iATTEND, HYCARET, and a French single-center trial) have similarly used two active comparator arms without a no-treatment control. This design relies on the ICH E10 constancy assumption rather than re-establishing assay sensitivity with concurrent trial data.
Outcome hierarchy: Given the number of secondary endpoints assessed in the pilot without multiplicity correction, this trial pre-specifies a hierarchical (fixed-sequence) gatekeeping procedure to control the family-wise type I error rate: Gate 1 tests the primary non-inferiority hypothesis on Peak VO2; Gate 2, tested only if Gate 1 is met, formally tests the pre-specified key secondary hypothesis on 6-month outpatient medical cost; Gate 3 outcomes (quality of life/QALY, medication adherence, secondary CPET indices, pulmonary function) are analyzed and reported descriptively as pre-specified but exploratory, without formal multiplicity control, and are entered under Other Pre-specified Outcome Measures below rather than Secondary Outcome Measures.
Missing data: Primary and secondary efficacy outcomes with missing values will be handled by multiple imputation (MICE, ≥20 imputations, pooled per Rubin's rules), with complete-case analysis as a sensitivity analysis. An interim analysis is planned at 50% enrollment for safety monitoring by an independent Data Safety Monitoring Board (DSMB); no interim efficacy testing is performed, so no alpha-spending adjustment is required. The interim analysis will also re-examine the actual randomization-acceptance rate against the 60% planning assumption and adjust the recruitment period or target if needed.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: SHENG-CHI Lo, BS. PT.
- Phone Number: +886-02-28264400 EXT 3459
- Email: fy10940619@gmail.com
Study Contact Backup
- Name: Yu-Shan Lin, PT, MSc, CRFC
- Phone Number: +886-02-28264400 EXT 3459
- Email: itsyushanlin@gmail.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Post-cardiac-surgery patients at the study hospital
- Age 20-75 years
- Low cardiovascular risk (AHA 2013 exercise training risk stratification, Class B), clinically stable
- Able to self-monitor exercise intensity
Exclusion Criteria
- High risk of sudden cardiac death
- Sustained atrial fibrillation or non-sustained ventricular tachycardia within the preceding 6 months
- Implanted cardioverter-defibrillator (ICD)
- Unable to independently operate the communication/exercise software or devices required for the home-based program
- Declines to undergo study testing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hybrid cardiac rehabilitation (Experimental)
Description:Weeks 1-2: 4 supervised hospital sessions (twice weekly). End of week 2: risk reassessment (AACVPR algorithm; patients with high-risk features do not transition to home) and teaching of home resistance exercise. Weeks 3-8: home aerobic exercise at least 3 times per week and elastic-band resistance exercise at least 2 times per week; remote 30-second ECG at rest daily and after each exercise session; exercise log; weekly telephone call; two standardized text messages per week; return visit at week 4. Participants choose this arm. |
Hybrid cardiac rehabilitation (hospital-to-home transition):as in Arm 1; aerobic intensity is based on the anaerobic-threshold heart rate from baseline CPET when available, otherwise moderate intensity (RPE 12-13); resistance exercise uses elastic bands (4-8 exercises, RPE 11-13) with sternal precautions; intensity at home does not exceed the hospital sessions; upper-limb movements at home are added only after individual confirmation by the therapist. |
|
Active Comparator: Standard center-based cardiac rehabilitation (Active Comparator)
Description:Two supervised hospital sessions per week for 8 weeks (16 sessions), plus weekly verbal encouragement to exercise on their own and a home exercise log. Exercise prescription follows the hospital routine and is made in the same way as in the hybrid arm. Participants choose this arm. |
Standard center-based cardiac rehabilitation:as in Arm 2. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Peak Oxygen Uptake (VO2peak) Measured by Cardiopulmonary Exercise Testing
Time Frame: Baseline (Week 0) and Week 8
|
Description:VO2peak (mL/kg/min) is the highest 30-second average oxygen uptake during a symptom-limited bicycle ramp cardiopulmonary exercise test with breath-by-breath gas analysis. Change = week 8 value minus week 0 value. Non-inferiority margin: 1.5 mL/kg/min. |
Baseline (Week 0) and Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak Oxygen Uptake (VO2peak) Measured by Cardiopulmonary Exercise Testing at 6 Months After Week 8
Time Frame: 6 months after week 8
|
Description:Key secondary outcome. VO2peak (mL/kg/min) measured as for the primary outcome. Tested in a fixed sequence only if non-inferiority is shown for the primary outcome. |
6 months after week 8
|
|
Number of Attended Supervised Exercise Sessions, From Hospital Attendance Records
Time Frame: Weeks 1-8.
|
Description:Count of supervised hospital sessions attended per participant (prescribed: 4 in the hybrid arm, 16 in the standard arm). |
Weeks 1-8.
|
|
Number of Home Exercise Sessions per Week, Recorded in the Home Exercise Log
Time Frame: Weeks 1-8.
|
Description:Mean number of self-reported home exercise sessions per week (aerobic and resistance), from the participant's home exercise log. |
Weeks 1-8.
|
|
Number of Participants Who Attend at Least 80% of Prescribed Supervised Sessions, From Hospital Attendance Records
Time Frame: Week 8.
|
Description:Participants attending at least 80% of the supervised sessions prescribed for their arm. |
Week 8.
|
|
Health Utility Measured by the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) Index Score Using the Taiwan Value Set
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
Description:The EQ-5D-5L describes health in 5 dimensions with 5 levels each; responses are converted to an index score with the Taiwan value set (Lin et al., PLoS One 2018). Index range -1.0259 to 1; 1 = full health; higher scores indicate better health. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Self-Rated Health Measured by the EuroQol Visual Analogue Scale (EQ VAS)
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
Description:EQ VAS ranges from 0 (worst imaginable health) to 100 (best imaginable health); higher scores indicate better health. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Six-Minute Walk Distance Measured by the 6-Minute Walk Test
Time Frame: Baseline (week 0) and week 8
|
Description:Distance walked in 6 minutes (meters). |
Baseline (week 0) and week 8
|
|
Patient Satisfaction Measured by the Client Satisfaction Questionnaire-8 (CSQ-8) Total Score
Time Frame: Week 8 and 6 months after week 8
|
Description:8 items each scored 1 to 4; total score ranges from 8 to 32; higher scores indicate greater satisfaction. |
Week 8 and 6 months after week 8
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Outpatient Visits, Excluding Cardiac Rehabilitation Sessions, From Hospital Records and National Health Insurance Data
Time Frame: From week 8 through 6 months after week 8
|
Count of outpatient visits per participant; cardiac rehabilitation sessions are excluded. |
From week 8 through 6 months after week 8
|
|
Number of Emergency Department Visits, From Hospital Records and National Health Insurance Data
Time Frame: From week 8 through 6 months after week 8
|
Count of emergency department visits per participant. |
From week 8 through 6 months after week 8
|
|
Number of Hospital Admissions, From Hospital Records and National Health Insurance Data
Time Frame: From week 8 through 6 months after week 8
|
Count of hospital admissions per participant. |
From week 8 through 6 months after week 8
|
|
Total Length of Hospital Stay, From Hospital Records and National Health Insurance Data
Time Frame: From week 8 through 6 months after week 8
|
Total inpatient days per participant. |
From week 8 through 6 months after week 8
|
|
Outpatient and Emergency Department Medical Expenditure, Excluding Cardiac Rehabilitation-Related Charges
Time Frame: From week 8 through 6 months after week 8
|
Total outpatient and emergency department medical expenditure per participant in New Taiwan Dollars (NTD), from hospital billing records and National Health Insurance data. |
From week 8 through 6 months after week 8
|
|
Inpatient Medical Expenditure
Time Frame: From week 8 through 6 months after week 8
|
Total inpatient medical expenditure per participant in NTD, from hospital billing records and National Health Insurance data. |
From week 8 through 6 months after week 8
|
|
Participant Time Spent on the Rehabilitation Program, Measured by a Study-Specific Time-Cost Questionnaire
Time Frame: Weeks 1-8
|
Total hours spent on travel to and from the hospital and on rehabilitation sessions (supervised and home-based) per participant. |
Weeks 1-8
|
|
Medication Adherence Measured by the 8-Item Morisky Medication Adherence Scale (MMAS-8)
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
Total score ranges from 0 to 8; higher scores indicate better adherence. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Number of Participants Reporting Current Tobacco Use, Assessed by Self-Report Questionnaire
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
Participants reporting any tobacco use in the past 30 days |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Muscle Mass Measured by Bioelectrical Impedance Analysis (ACCUNIQ BC720)
Time Frame: Baseline (week 0) and week 8
|
Muscle mass in kilograms. |
Baseline (week 0) and week 8
|
|
Body Fat Percentage Measured by Bioelectrical Impedance Analysis (ACCUNIQ BC720)
Time Frame: Baseline (week 0) and week 8
|
Body fat as a percentage of body weight. |
Baseline (week 0) and week 8
|
|
Forced Vital Capacity (FVC) Measured by Spirometry
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
FVC in liters. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Forced Expiratory Volume in 1 Second (FEV1) Measured by Spirometry
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
FEV1 in liters. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Ratio of FEV1 to FVC (FEV1/FVC) Measured by Spirometry
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
FEV1/FVC expressed as a percentage. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Minute Ventilation to Carbon Dioxide Output Slope (VE/VCO2 Slope) Measured by Cardiopulmonary Exercise Testing
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
Slope of the linear relationship between minute ventilation and carbon dioxide output during exercise (unitless); lower values indicate better ventilatory efficiency. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Oxygen Uptake Efficiency Slope (OUES) Measured by Cardiopulmonary Exercise Testing
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
Slope of oxygen uptake (mL/min) against the log10 of minute ventilation (L/min); higher values indicate better efficiency. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Oxygen Uptake at the First Ventilatory Threshold (VO2 at VT1) Measured by Cardiopulmonary Exercise Testing
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
VO2 at the first ventilatory threshold in mL/kg/min. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Heart Rate Recovery at 1 Minute (HRR1) After Cardiopulmonary Exercise Testing
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
Peak heart rate minus heart rate 1 minute into recovery, in beats per minute; higher values indicate better recovery. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Heart Disease-Specific Quality of Life Measured by the MacNew Heart Disease Health-Related Quality of Life Questionnaire Global Score
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
27 items; global score ranges from 1 to 7; higher scores indicate better health-related quality of life. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Depressive Symptoms Measured by the Patient Health Questionnaire-9 (PHQ-9) Total Score
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
Total score ranges from 0 to 27; higher scores indicate more severe depressive symptoms. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Anxiety Symptoms Measured by the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score
Time Frame: Baseline (week 0), week 8, and 6 months after week 8
|
Total score ranges from 0 to 21; higher scores indicate more severe anxiety symptoms. |
Baseline (week 0), week 8, and 6 months after week 8
|
|
Number of Participants With Adverse Events During Exercise Testing, Supervised Training or Home Exercise
Time Frame: From baseline (week 0) through 6 months after week 8 (approximately 8 months)
|
Adverse events include cardiovascular events (e.g., arrhythmia requiring intervention, angina, syncope, abnormal blood pressure response, myocardial infarction, stroke, death), musculoskeletal injury and sternal wound complications, recorded by therapists, the remote ECG review, the exercise log and weekly telephone calls. |
From baseline (week 0) through 6 months after week 8 (approximately 8 months)
|
|
Number of Participants Who Discontinue the Intervention
Time Frame: Weeks 1-8
|
Participants who stop the assigned intervention for any reason; reasons are reported. |
Weeks 1-8
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yu-Shan Lin, PT, MSc, CRFC, Chief Physical Therapist, Cheng Hsin General Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CHGH115-114-18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.